Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production
about
PD-L1 expression induced by the 2009 pandemic influenza A(H1N1) virus impairs the human T cell responseNo evidence for dualism in function and receptors: PD-L2/B7-DC is an inhibitory regulator of human T cell activationRole of PD-1 in HIV pathogenesis and as target for therapyActive systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1Dominating expression of negative regulatory factors downmodulates major histocompatibility complex Class-II expression on dendritic cells in chronic hepatitis C infectionThe immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placentaModulation of Innate Immune Mechanisms to Enhance Leishmania Vaccine-Induced Immunity: Role of Coinhibitory MoleculesProgrammed Cell Death-1 Polymorphisms Decrease the Cancer Risk: A Meta-Analysis Involving Twelve Case-Control StudiesGeneration of Tolerogenic Dendritic Cells and Their Therapeutic ApplicationsProgrammed death-1/programmed death-L1 signaling pathway and its blockade in hepatitis C virus immunotherapyRole of the PD-1 pathway in the immune responseThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunityLung cancer: a classic example of tumor escape and progression while providing opportunities for immunological interventionDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trialsIn vivo T cell activation induces the formation of CD209(+) PDL-2(+) dendritic cellsThe expression of PD-1 ligands and their involvement in regulation of T cell functions in acute and chronic woodchuck hepatitis virus infectionB7-H1 blockade increases survival of dysfunctional CD8(+) T cells and confers protection against Leishmania donovani infectionsPD-1 Expression in Acute Hepatitis C Virus (HCV) Infection Is Associated with HCV-Specific CD8 ExhaustionLiver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 ExpressionViral replication and paracrine effects result in distinct, functional responses of dendritic cells following infection with dengue 2 virusSynergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 BlockadeFunctional Restoration of HCV-Specific CD8 T Cells by PD-1 Blockade Is Defined by PD-1 Expression and CompartmentalizationEpitope characterization of an anti-PD-L1 antibody using orthogonal approachesThe blockade of immune checkpoints in cancer immunotherapyThe PD1:PD-L1/2 Pathway from Discovery to Clinical ImplementationIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsPD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinationsTolerance in liver transplantation: Biomarkers and clinical relevanceDendritic Cell-Based Immunotherapy Treatment for Glioblastoma MultiformeThe Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaContribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasionThe role of the PD-1 pathway in autoimmunity and peripheral toleranceBovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cellsPD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progressionImmunosuppressive networks in the tumour environment and their therapeutic relevanceColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapePD-L1 regulates the development, maintenance, and function of induced regulatory T cellsPD-L1, PD-L2 and PD-1 expression in metastatic melanoma: Correlation with tumor-infiltrating immune cells and clinical outcome.Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialBoth PD-1 ligands protect the kidney from ischemia reperfusion injury.
P2860
Q24339361-9ACA853D-7ABD-442A-9D1D-B4025F85DF26Q24613354-6A68E7BB-64DA-429F-B466-759FCB0458B4Q24634293-DD611FAC-1ACF-4F29-AF7A-1D4768B4CCCDQ24655393-8D3AB8B8-7610-4D32-A608-C41409E12D6DQ24658465-7B9B9B59-C6E9-47F8-908C-18EDB44C74EDQ24675388-C67B2611-C3FB-4B8B-A1EA-05F57A3F3031Q26744635-76D213E7-A8B7-4413-A9B4-47F862739D37Q26749244-455BF398-F0CE-426A-9405-C8357E64E71CQ26764855-8281A4D6-9A7B-4E72-AB06-ED79B6D23BD5Q26781481-C1DF0E22-9152-4CEC-90DE-AD9B4E52643CQ26828748-857BD037-1569-4514-95F8-8266B1F67A90Q26829847-F2DD7C8A-2923-476C-9C7F-A9E60CA7E910Q26850218-3A786802-7D53-4CCF-8E7B-6CA99B6CC661Q27014829-95A35C57-6543-44A6-9C38-EDF879C8719EQ27304762-0C989F54-440B-4BAF-BE9A-A020324D0133Q27316653-261A92B3-8064-4C26-B151-A09E3D544F59Q27317015-90E699E6-10CC-4E58-86C7-792EE1A6379BQ27477628-0C3B3EE6-B460-4666-A077-5EF523277729Q27478366-C8BBCAA8-1B91-4E17-8FC4-50235A850B71Q27486878-706A5751-3A63-43E4-B04F-9019539947BEQ27487939-B1D6EE6B-4D59-4F7D-9A31-8F01A78B2402Q27488289-91EFB242-9F31-4804-B360-237E94273DB9Q27697932-4F25D244-C2BA-412C-AF52-CE315CD04B30Q27860852-5C70441F-78CA-4FD7-8921-FEA6E9CCCB9BQ28066941-F5C328B5-9989-4D99-8453-69DDBF166A43Q28072532-D97ECD9E-A8F2-46A6-A93A-6E0DEC638B23Q28075712-9CB9D576-C2B7-4DA9-B53A-7780A52B529BQ28079523-CF4A5739-0F76-4D8F-ADF8-08D579F4BE09Q28087485-B92F62E9-076D-4A8E-AB45-7D6A9D1E7A5AQ28088496-C43E4674-6450-4222-8676-D34EDFA6C419Q28281101-579CA140-7654-46E1-BFE7-85DEEA3BC349Q28304161-1D2D6144-64BD-4D0E-8537-F92948D8123FQ28742177-7C952A74-A1D4-4036-A0AE-78A4304F8E32Q29618956-F8D58A61-7239-485A-B8B4-981E89FA7CC4Q29619244-C25E0929-F222-4B46-857A-1035AED734AEQ29620881-06A7C15F-2928-433B-B80A-645816A44C3EQ30080038-4A569A3F-A6A1-407F-A769-F8595AD47F2AQ30275174-5E22878D-16B7-4491-8018-CD56F01DC438Q30277192-3FE9CB4A-6E78-40E5-BAA3-3C92CD9CCA53Q30301290-328DB4FF-49D7-4EFF-93A1-4620DE537A67
P2860
Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Blockade of programmed death-1 ...... vation and cytokine production
@ast
Blockade of programmed death-1 ...... vation and cytokine production
@en
Blockade of programmed death-1 ...... vation and cytokine production
@en-gb
Blockade of programmed death-1 ...... vation and cytokine production
@nl
type
label
Blockade of programmed death-1 ...... vation and cytokine production
@ast
Blockade of programmed death-1 ...... vation and cytokine production
@en
Blockade of programmed death-1 ...... vation and cytokine production
@en-gb
Blockade of programmed death-1 ...... vation and cytokine production
@nl
prefLabel
Blockade of programmed death-1 ...... vation and cytokine production
@ast
Blockade of programmed death-1 ...... vation and cytokine production
@en
Blockade of programmed death-1 ...... vation and cytokine production
@en-gb
Blockade of programmed death-1 ...... vation and cytokine production
@nl
P2093
P921
P3181
P1476
Blockade of programmed death-1 ...... vation and cytokine production
@en
P2093
Clive R Wood
David M Dorfman
Edward A Greenfield
Elizabeth L Sullivan
Feng-Rong Ma
Gordon J Freeman
Julia A Brown
Oliver Munoz
P304
P3181
P356
10.4049/JIMMUNOL.170.3.1257
P407
P577
2003-02-01T00:00:00Z